PCN85 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EORTC QLQ-C30  by Lundy, JJ et al.
A52 Abstracts
PCN82
HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS
WITH HAND-FOOT SYNDROME
Taieb C1, Sibaud V2
1Pierre Fabre, Boulogne, France, 2AVENE, LAVAUR, France
Hand-foot syndrome or palmar-plantar erythrodysesthesia is a common adverse effect
of certain chemotherapy agents, such as capecitabine or pegylated doxorubicin, where 
it is estimated to occur in 50% of cases. It is also frequently reported with some new
targeted anticancer therapies, such as sorafenib or sunitinib, although its clinical pre-
sentation is slightly different. OBJECTIVES: To develop and validate a hand-foot 
syndrome-speciﬁ c quality of life scale in order to be able to measure the impact of the 
condition on patients and to be able to assess the value of certain speciﬁ c treatments 
in this indication. METHODS: The questionnaire was developed after conducting a 
series of structured interviews with patients with forms of hand-foot syndrome of 
varying severity, which yielded a detailed and rigorous collection of verbatim tran-
scripts. RESULTS: Thirty-one items were identiﬁ ed, and 14 items were selected as
being relevant and non-overlapping after initial evaluation. The ﬁ rst question in the 
HFS14 addresses which member is affected (hand, foot or both). The second question 
addresses the pain with three possible responses (very, moderately or not painful). The
14 items can be organised in 2 modules: the ﬁ rst module more speciﬁ cally assesses the
handicap generated by involvement of the feet and the second assesses the handicap 
generated by involvement of the hands. Six items are considered common to both 
modules, four are hand-speciﬁ c and four are foot-speciﬁ c. Psychometric validation 
conﬁ rmed the internal consistency and very high reproducibility of the questionnaire.
CONCLUSIONS: The hand-foot syndrome-speciﬁ c HFS14 scale is easy to use and 
meets the requirements of a quality of life scale. This scale now needs to be tested in
longitudinal studies for example in clinical trials to conﬁ rm its ability to measure a 
change in status.
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A MULTINATIONAL STUDY OF PATIENT PREFERENCE VALUES FOR 
HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKEMIA
Szabo SM1, Davis C2, Cortes J3, Levy AR1
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Bristol-Myers Squibb, Wallingford, CT, USA, 
3MD Anderson Cancer Center, Houston, TX, USA
OBJECTIVES: Studies of preferences in many disease areas show that patients
valuate health states higher than general public respondents. We previously elicited
general public preferences for chronic myelogenous leukemia (CML) health states.
The objectives here were to 1) estimate preferences for CML health states from
US, UK, Canadian, and Australian patients, and 2) determine if adjusted point esti-
mates of patient preferences for CML health states were higher than those of general 
public respondents. METHODS: Time trade-off preference values for six CML health
states were elicited from CML patients by trained interviewers using a script. Stan-
dardized health state descriptions were derived in consultation with a panel of oncolo-
gists. Mean health state preferences were calculated and a generalized linear model 
used to determine signiﬁ cant predictors. While statistical comparisons were not appro-
priate, point estimates of patient preferences were compared against known general
public preferences for CML health states. RESULTS: Ninety-three patients were
included, from the US (n  33, 35%), UK (n  11; 12%), Canada (n  24; 26%), and 
Australia (n  25; 27%). The mean age was 52 years (range, 20–79) and 60% were 
men. Signiﬁ cant differences were observed in mean patient preferences between the 
countries. After adjustment for country, age and sex, mean patient preferences were:
0.95 for chronic phase responding (CR); 0.76 for chronic phase non-responding
(CNR); 0.84 for accelerated phase responding (AR); 0.54 for accelerated phase 
non-responding (ANR); 0.38 for blast phase responding (BR); and 0.27 for blast 
phase non-responding (BNR). Except for BR, all point estimates of general public 
preferences were lower than patient values, and were: 0.91 (CR); 0.73 (CNR); 0.78 
(AR); 0.49 (ANR); 0.48 (BR); and 0.22 (BNR). CONCLUSIONS: This study provides 
evidence that preferences for oncological health states follow the pattern expected if 
habituation were taking place, and patients report higher preferences than general 
public representatives.
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VALIDATION OF THE EUROQOL EQ-5D IN PATIENTS WITH RELAPSED/
REFRACTORY MANTLE CELL LYMPHOMA (RR MCL)
Cuyun Carter G1, Liepa AM1, Zimmermann AH1, Morschhauser F2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Centre Hospitalier Universitaire, Lille, France
OBJECTIVES: Health utilities, measured by the EQ-5D, have not been reported 
for MCL, an aggressive form of non-Hodgkin’s lymphoma. This research aimed to
explore the validity of the EQ-5D in patients with RR MCL and to estimate minimally 
important differences (MIDs). METHODS: Data were collected in a phase II, single-
arm, open-label study of enzastaurin in RR MCL patients (Morschhauser et al, Ann 
Oncol 2008). Criterion validity was assessed by grouping patients by International
Prognostic Index (IPI) and by Eastern Cooperative Oncology Group performance
status (PS). Responsiveness to change was assessed by grouping patients according to
changes in PS (improved/stable or worse) and disease status. Distribution- and anchor-
based methods were used to estimate MIDs. RESULTS: EQ-5D data were available 
for 58 of 60 enrolled patients at baseline and for 38 patients at discontinuation. 
Median age was 66 years, 70% were male, 88% had a baseline PS of 0 or 1, and
52% had an IPI score a2. There was a statistically signiﬁ cant (p  0.05) difference in
baseline EQ-5D index (0.81, 0.63, 0.58) and visual analogue scale (VAS) (66.9, 56.4, 
44.7) by PS group (0, 1, 2, respectively) and at discontinuation by PS group for the 
index (0.77, 0.61, 0.28). There were no signiﬁ cant differences for the index or VAS
scores by IPI group. Those patients with worsened PS (n  12) had signiﬁ cantly worse
index and VAS scores than those patients with improved/stable PS (n  18). The 
estimated MID ranges across the varying methodologies were 0.05–0.10 for the 
index and 5.2–10.0 for the VAS. CONCLUSIONS: This retrospective study provides
evidence that the EQ-5D is a valid instrument to assess health status in patients with 
RR MCL, based on differentiation of patients by clinical status. The estimated MIDs
are consistent with those reported for other cancers and will be helpful in designing 
future studies.
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TESTING THE MEASUREMENT EQUIVALENCE OF PAPER 
AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF
THE EORTC QLQ-C30
Lundy JJ1, Coons SJ1, Aaronson NK2
1University of Arizona, Tucson, AZ, USA, 2The Netherlands Cancer Institute, Amsterdam, 
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OBJECTIVES: When migrating existing patient-reported outcome measures to elec-
tronic data capture technologies, it is critically important that the new modes of 
administration provide comparable results to the original. The objective of this study
was to evaluate the measurement equivalence of an interactive voice response (IVR) 
version to the original paper-based version of the EORTC QLQ-C30. METHODS:
The QLQ-C30 is a cancer-speciﬁ c health-related quality of life measure consisting of 
nine multi-item scales (physical, role, emotional cognitive and social functioning, 
fatigue, emesis and global health/quality of life) and six single item measures (dyspnoea,
insomnia, appetite loss, constipation, diarrhoea, and ﬁ nancial problems). This study 
utilized a crossover design with subjects randomly assigned to one of two assessment
orders: 1) paper then IVR, or 2) IVR then paper. Cancer patients receiving treatment
on an outpatient basis (n  139) were asked to complete each assessment two days 
apart. Equivalence between the two administration modes was established by compar-
ing the 95% lower conﬁ dence interval (CI) of the intraclass correlation coefﬁ cients 
(ICCs) for each scale, with a critical value of 0.70. RESULTS: The ICCs for the nine 
multi-item scales were all above 0.79, ranging from 0.791 to 0.899 (ICC 95% lower
CI range: 0.726 to 0.865), and signiﬁ cantly different from our threshold reliability of 
0.70. The ICCs for the six single items ranged from 0.689 to 0.896 (ICC 95% lower 
CI range: 0.611 to 0.888). Two of the items, insomnia and appetite loss, were not sta-
tistically different from 0.70. Thus, we do not denote equivalence based on the ICCs
for these two items. However, when taken together, the results support the equivalence
of the scores between the paper and IVR versions of the QLQ-C30. CONCLUSIONS:
This analysis provides evidence that the scores obtained from the IVR version of the 
QLQ-C30 are equivalent to those obtained with the original paper version.
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TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE RESPONSE (IVR)
VERSION OF THE EQ-5D IN A SAMPLE OF CANCER SURVIVORS
Lundy JJ, Coons SJ
University of Arizona, Tucson, AZ, USA
OBJECTIVES: The objective of this study was to assess the test-retest reliability of an 
interactive voice response (IVR) version of the EQ-5D. METHODS: The EQ-5D self-
report questionnaire consists of a descriptive system and a visual analog scale (EQ
VAS). Responses on the descriptive system classify the respondent into one of 243 
unique health states. A preference weight is assigned to the health state, resulting in
an EQ-5D index score on a scale where 1  perfect health and 0  death. Cancer clinic 
patients (n  127) were asked to complete the IVR-based EQ-5D twice, two days
apart. The analyses tested for mean differences (paired t-test) and test-retest reliability 
(ICC) to assess measurement stability over time. Equivalence of the means was estab-
lished if the 95% conﬁ dence interval (CI) was within the minimally important differ-
ence (MID) interval, namely .025 to .025 for the index and 3 to 3 for the EQ-VAS. 
Adequacy of the ICC was established by comparing the ICC 95% lower CI with a 
critical value of 0.70. RESULTS: Both administrations were completed per protocol 
by 110 subjects (EQ-5D index) and 114 subjects (EQ VAS). For the EQ-5D index, the
means (SD) of the ﬁ rst and second administrations were 0.871 (0.138) and 0.868
(0.153), respectively. The 95% CI of the mean difference was 0.012 to 0.017, which 
was within the equivalence interval. The ICC was 0.858 (0.800 – 0.901) and was sig-
niﬁ cantly different from 0.70 (p  0.001). For the EQ VAS, the means (SD) were 81.34
(17.46) and 80.83 (17.52), respectively. The 95% CI of the mean difference was 
0.598 to 1.617, which was within the equivalence interval. The ICC was 0.944
(0.919 – 0.961) and was signiﬁ cantly different from 0.70 (p  0.001). CONCLU-
SIONS: This analysis provides substantial evidence that the scores obtained from the 
IVR version of the EQ-5D are reliable upon repeated administrations.
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TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE 
RESPONSE (IVR) VERSION OF THE EORTC QLQ-C30
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1University of Arizona, Tucson, AZ, USA, 2The Netherlands Cancer Institute, Amsterdam, 
Netherlands
OBJECTIVES: The objective of this study was to assess the test-retest reliability of 
an interactive voice response (IVR) version of the EORTC QLQ-C30. METHODS: A 
convenience sample of outpatient cancer clinic patients (n  127) was asked to com-
plete the IVR version of the QLQ-C30 twice, two days apart. The QLQ-C30 is a 30-
item, cancer-speciﬁ c questionnaire composed of single-items and multi-item scales. The 
